The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
"we need revenue information"
Quite BC, my hunch is we have been selling quietly in the background, maybe not in huge numbers, but probably a few million a month.
It makes me smile when the more obvious derampers shout, "no LFT sales", as you say, when the H2 figures are released, we should get a sensible rereate if I am right.
The other significant SP driver will be when we get data about the AVA6000 trial, AS says he can't comment, but is very pleased so far, or words to that effect.
I am looking forward to early next year, when I think this share will finally start to take off. Call me a ramper, but this is what the available evidence is pointing to IMO.
Love your post Dave, "never mind the quality, feel the width", has definitely been the UK govs MO up to now.
Unfortunately, as a white goods seller, and my own experience selling boilers, most of the British public are what is called "price sensitive", so when LFT's are no longer free, the majority will go for the cheapest.
I am heavily (for me) invested, and so want AVCT to fly, but I am more excited by sales to Europe, and the rest of the world, and of course AVA6000, the real potential holy grail!
Just got back in, thanks gmcc, and RD, if only all the posters here were as polite and helpful.
I check in most days, but if I see a thread with personal attacks from either side, I (like most I would guess) stop reading.
@D0berman, that link is broken it seems?
I found this
https://www.globenewswire.com/news-release/2020/11/10/2123598/0/en/POINT-Biopharma-and-Bach-Biosciences-announce-licensing-and-partnership-for-canSEEK-pan-cancer-targeting-technology.html
I'm sure this must have been covered, but I missed it. Point only mention licencing with Bach (the inventor from turfs uni?)
so does that mean Avacta are not the only ones using or developing this FAP tech?
Well put Code J, that's where I am at, I think all of the more vulnerable should be jabbed, NOT kids, and offered a jab, not coerced with threats backed by the law.
Sorry for my sarcasm BC, we will have agree to disagree on this one, meanwhile, I see the is holding the 1 - 0s again, strong support until good news RNSs!
"The HMG should enforce a lockdown on all those who are unvaccinated"
Sorry blackcat, but I strongly disagree, no government should have a two tier system for human rights, based on a medical procedure. (with the possible exception of work related provisos)
A very nasty start to a slippery slope.
So the UKHSA has only approved three, but read the statement carefully,
"Additionally, the UK Health Security Agency has published a temporary protocol which lists 48 tests (both PCR and antigen based) which passed the Public Health England validation process at Porton Down earlier in the year that can remain available for sale in the UK whilst their validation is completed until a cut-off date of 28 February 2022."
So which tests are they going to prioritise to process next, logic would say those 48. Because Porton downs frozen samples didn't suit our test, I'm afraid we can forget getting validation in the UK any time soon.
I would of course love to be proved wrong, but hope, and think that we are selling all we can make into other markets, likely about 2 million a month. The fact that AS has said he is very happy with the AVA6000 trial, and we have had no news, (if pulled, would have to be RNSed), makes me quite comfortable with the future prospects of Avacta, last chance for a top up?
On one of the news sites,
"Molnupiravir is for people who have had a positive Covid test"
So testing will still be required, I don't see how this affects Avacta, unless possibly positively.
I've just read a piece about Arm China's boss going rogue.
It seems Chinese companies sometimes copy or steal tech from western companies.
this has me a little concerned, don't we have a tie in with a Chinese manufacturer?
Gruffell, yes you have a point, but my take is he is only obliged to RNS news likely to affect the SP, if it goes from 2.80 to 80p, and it's just the market ( buyers and sellers), not his problem.
If the entire SAB have resigned, and that is affecting the SP, I would expect a RNS.
Sorry Gruffell, but I have to agree with Ndn, I'm underwater, but a paper loss is just that unless you sell.
Also, you aren't the only one calling for something from AS, well it is not his job to react to share price fluctuations, the last time he did was because a rumour was affecting the SP.
I for one am happy with the way he runs the company (apart from timeline slips!) and get fed up with reading "why doesn't Al explain the SP fall" etc.
Lolarch,
Nobody seems keen to reply to your question so I'll give it a go
Either existing shareholders receive some shares in the new or buyout company, or more commonly, the money is kept in the original company, and either saved, spent or returned to share holders as a dividend, or a combination.
So
The SP should stay the same, or go up, if the buyout was deemed by the market as a good price. So all depends on the details of the deal!
The opposite would apply if a co. was in financial trouble, and sold part of the co to get money. They may sell cheap, and then spend that money for little gain, making the original company smaller so worth less. I don't think AVCT are in that position though!
Hmm, I did wonder, and worry about this back in February was it when the GAD tie up was announced.
I guess we will find out tomorrow, but I don't see why everyone is getting so excited.
If Avactas affimers, or mologic made LFTs are going to Africa, while very worthy and all that, I guess Avacta won't be making any money of them.
I'm sorry, but I am invested to make money, charity can come later, all the world kudos does not pay my bills.
Put me right if I've misunderstood this news?